Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Eisai Co., Ltd.
- 8,702.00 JPY
- +44.00
- +0.51%
Japan
Jan 24, 2019Ticker
TKS(4523)Prev. close
8,658Market cap (JPY)
2,567.67BMarket cap (USD)
23,420.22MShares
296.56M
In the news
- 'Robot taxes' will help keep humans employed, Bill Gates predicts Nov 3, 2018
- Eisai teams with Merck to boost sales of cancer drug Mar 9, 2018
- China sees influx of blockbuster drugs as market grows Mar 5, 2018
- Japanese bioventures receiving healthy dose of investor funds Jan 24, 2018
- Sumitomo Dainippon eyes higher psychiatric drug sales in China Nov 16, 2017 See more articles on Eisai Co., Ltd.
Business Summary
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Financial Highlights
| Mar 2018 | JPY | USD |
| Revenue | 600,054M | 5,414.06M |
| Gross Profit | 386,599M | 3,488.14M |
| Operating income | 75,595M | 682.06M |
| Income before tax | 76,803M | 692.96M |
| Net income | 51,845M | 467.77M |
| EBITDA | 101,778M | 918.30M |
| Diluted EPS | 180.97 | 1.63 |
| Dividends Per Share | 150 | 1.35 |
| Total Assets | 1,049.03B | 9,863.94M |
| Total liabilities | 434,934M | 4,089.64M |
| Total equity | 593,582M | 5,581.39M |
| Operating cash flow | 149,649M | 1,350.22M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 599,490M | 548,465M | 547,922M | 539,097M | 600,054M |
| Gross Profit | 390,525M | 340,580M | 339,839M | 331,091M | 386,599M |
| Operating income | 64,373M | 27,778M | 42,779M | 51,205M | 75,595M |
| Income before tax | 62,298M | 25,875M | 50,473M | 57,668M | 76,803M |
| Net income | 38,251M | 43,254M | 54,933M | 39,359M | 51,845M |
| EBITDA | 104,302M | 66,718M | 76,843M | 77,689M | 101,778M |
| Diluted EPS | 134.01 | 151.37 | 191.76 | 137.41 | 180.97 |
| Dividends Per Share | 150 | 150 | 150 | 150 | 150 |
| Total Assets | 973,823M | 1,053.81B | 973,987M | 1,030.76B | 1,049.03B |
| Total liabilities | 444,418M | 451,757M | 397,159M | 428,172M | 434,934M |
| Total equity | 526,321M | 598,748M | 573,660M | 584,630M | 593,582M |
| Operating cash flow | 91,276M | 76,022M | 95,617M | 75,851M | 149,649M |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 5,984.63M | 4,992.55M | 4,562.81M | 4,978.38M | 5,414.06M |
| Gross Profit | 3,898.56M | 3,100.22M | 2,830.00M | 3,057.51M | 3,488.14M |
| Operating income | 642.62M | 252.85M | 356.24M | 472.86M | 682.06M |
| Income before tax | 621.91M | 235.53M | 420.31M | 532.54M | 692.96M |
| Net income | 381.85M | 393.73M | 457.45M | 363.46M | 467.77M |
| EBITDA | 1,041.23M | 607.31M | 639.90M | 717.43M | 918.30M |
| Diluted EPS | 1.33 | 1.37 | 1.59 | 1.26 | 1.63 |
| Dividends Per Share | 1.49 | 1.36 | 1.24 | 1.38 | 1.35 |
| Total Assets | 9,455.96M | 8,787.30M | 8,665.75M | 9,250.32M | 9,863.94M |
| Total liabilities | 4,315.36M | 3,766.99M | 3,533.60M | 3,842.51M | 4,089.64M |
| Total equity | 5,110.65M | 4,992.68M | 5,103.96M | 5,246.61M | 5,581.39M |
| Operating cash flow | 911.19M | 692.01M | 796.24M | 700.45M | 1,350.22M |
Valuation Measures
| Mar 2018 | |
| PER | 37.42 |
| ROA | 4.98% |
| ROE | 8.80% |
| Operating margin | 12.59% |
| Profit margin | 8.64% |
Key executives
- Chief Executive Officer & Representative Director: Haruo Naito
- Chief Financial Officer & Chief IR Officer: Ryohei Yanagi
- Chief Information Officer: Hideki Hayashi
- Chief Compliance Officer & Executive Officer: Junichi Asatani
- Vice President: Yasunobu Kai
Shareholders
- Wellington Management Co. LLP (8.6%)
- Nomura Asset Management Co., Ltd. (5.0%)
- Nippon Life Insurance Co. (4.1%)
- Eisai Co., Ltd. (3.4%)
- BlackRock Fund Advisors (2.8%)
- Nikko Asset Management Co., Ltd. (2.7%)
- Daiwa Asset Management Co. Ltd. (2.4%)
- Resona Holdings, Inc. (2.4%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.4%)
- The Vanguard Group, Inc. (2.2%)
Contact Details
- Website:http://www.eisai.co.jp
- Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
- Phone: +81.3.3817.3700
Related Companies
- Eisai LLC
- Eisai Machinery China Co. Ltd.
- Eisai Laboratorios S de RL de CV
- Eisai GesmbH
- Eisai Farmaceutica, Unipessoal Lda.
- Eisai Clinical Research Singapore Pte Ltd.
- Eisai Ltd. (Canada)
- Eisai SA/NV
- Eisai (Malaysia) Sdn. Bhd.
- Eisai (Thailand) Marketing Co. Ltd.
- Eisai AB
- Eisai Pharma AG
- Eisai (Singapore) Pte Ltd.
- Eisai Co. Ltd. /Misato Factory/
- Eisai Board Incentive Plan
- Elmed Eisai Co. Ltd.
- Eisai Corporate Pension Fund
- Eisai Pension Fund
- Eisai China, Inc.
- H3 Biomedicine, Inc.
- Herusu Co., Ltd.
- Gakuen Shoji Co., Ltd.
- PT Eisai Indonesia
- Eisai Taiwan, Inc.
- Eisai (Hong Kong) Co. Ltd.
- Eisai Australia Pty Ltd.
- Eisai Pharmaceuticals India Pvt Ltd.
- Eisai GmbH
- Eisai SRL
- Eisai London Research Laboratories Ltd.
Competitors
- Ipsen SA
- Nektar Therapeutics
- Celgene Corporation
- Binex Co., Ltd
- Exelixis, Inc.
- Sienna Biopharmaceuticals, Inc.
- Kiniksa Pharmaceuticals Ltd. Class A
- ArQule, Inc.
- Blueprint Medicines Corp.
- Calithera Biosciences, Inc.
- Loxo Oncology Inc
- Denali Therapeutics Inc.
- SillaJen, Inc.
- Aquestive Therapeutics, Inc.
- Aslan Pharmaceuticals Ltd.
- Infinity Pharmaceuticals, Inc.
- Seattle Genetics, Inc.
- arGEN-X SE
- Orexigen Therapeutics, Inc.
- Probiodrug AG
- Heron Therapeutics Inc
- Onxeo SA
- ProMIS Neurosciences Inc.
- VIVUS, Inc.
- ACADIA Pharmaceuticals Inc.
- Aileron Therapeutics, Inc.
- Onconova Therapeutics Inc.
- AVEO Pharmaceuticals, Inc.
- Cytokinetics, Incorporated
- Insys Therapeutics, Inc.
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Jan, 2019Your full access to the Nikkei Asian Review has expired
